Website:www.tevapharm.com www.activebiotech.com

  * Positive benefit-risk profile of laquinimod sustained in Phase II extension
  * 52 percent reduction (p=0.0006) in mean number of gadolinium-enhancing (GdE)
    T1 lesions
  * Results from pivotal Phase III studies, ALLEGRO and BRAVO, anticipated in

Jerusalem,  Israel,  September  20, 2010 --  Teva Pharmaceutical Industries Ltd.
(NASDAQ:  TEVA) and  Active Biotech  (NASDAQ OMX  NORDIC: ACTI)  today announced
 results   from  a  36-week active  extension  study  evaluating  two  doses  of
laquinimod,   an  investigational,  once-daily  oral  immunomodulator,  for  the
treatment  of relapsing  remitting multiple  sclerosis (RRMS). The double-blind,
multinational  study demonstrated the sustained positive benefit-risk profile of
laquinimod,  which  was  shown  to  reduce  Gd-enhancing (GdE) T1 lesions, while
maintaining  a good safety profile. These  findings were published online by the
journal Multiple Sclerosis.
Patients  originally randomized to placebo in the core Phase II study, LAQ/5062,
 (published  in  The  Lancet*)  were  re-randomized  to  either 0.3 mg or 0.6 mg
laquinimod  for  the  extension  study,  while patients originally randomized to
active  treatment continued with the same treatment assignment for an additional
36 weeks.  Patients switching from placebo to  an active treatment of laquinimod
showed  a 52 percent reduction in  the mean number of  GdE lesions (p=0.0006), a
marker  of  disease  activity.   In  patients  initially  randomized  to  0.6 mg
laquinimod,  the  reduction  of  MRI  activity  was  maintained.   Additionally,
treatment  with laquinimod was associated with  a sustained reduction in relapse
rate, no evidence of immunosuppression and good safety and tolerability profile.

"The  results from this  extension study confirm  the balanced efficacy, safety,
and tolerability profile seen with laquinimod to date," explains Giancarlo Comi,
M.D.,  the lead study author and the Director of the Department of Neurology and
Institute of Experimental Neurology at the University Vite Salute, San Raffaele.
"We  look forward to the  results of the Phase  III ALLEGRO and BRAVO studies in
2011, and  the potential of this  novel agent to address  the current unmet need
for MS patients seeking a safe, effective and well tolerated oral therapy."

Laquinimod  received  Fast  Track  designation  from  the  U.S.  Food  and  Drug
Administration  (FDA) in February  2009. Two global Phase  III clinical studies,
ALLEGRO  and BRAVO are currently ongoing, with results anticipated during Q1 and
Q3 2011, respectively.

*  Comi G. et al. (2008). Effect of laquinimod on MRI-monitored disease activity
in   patients  with  relapsing  remitting  multiple  sclerosis:  a  multicentre,
randomized,  double-blind,  placebo-controlled  phase  IIb  study.  The  Lancet;

The multinational, double-blind, 36-week extension of the placebo-controlled
Phase IIb laquinimod study was conducted in 9 countries at 51 sites. Two hundred
thirty-nine (93 percent) patients completed the extension phase of the study and
222 (87.1 percent) had a final scan. GdE lesions were significantly reduced for
patients switching from placebo to 0.3 or 0.6mg doses (52 percent, p = 0.0006).
In patients initially randomized to 0.6 mg, the reduction of MRI activity
observed in the placebo-controlled phase was maintained in the extension. The
proportion of GdE-free patients for those who switched from placebo increased
from a baseline of 31 percent to 47 percent at the end of the extension phase (p
= 0.01).  No new adverse events emerged during the extension study. The
incidence rate of liver enzymes elevation observed in the LAQ/5062 core study
decreased in the extension phase.

Laquinimod is an investigational, novel, once-daily oral immunomodulator being
developed as a disease-modifying treatment for RRMS. Active Biotech developed
laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June
2004. A Phase IIb study in 306 patients was published in The Lancet and
demonstrated that an oral 0.6 mg dose of laquinimod, administered daily,
significantly reduced MRI disease activity by 60 percent versus placebo in RRMS
patients. In addition, the study showed a favorable trend toward reducing annual
relapse rates and the number of relapse-free patients compared with placebo.
Treatment was well tolerated, with only some transient and dose-dependent
increases in liver enzymes reported.

Two pivotal, global Phase III studies of laquinimod for the treatment of RRMS,
ALLEGRO and BRAVO, are nearing completion. ALLEGRO, a 24-month multinational,
double-blind, placebo-controlled study, designed to evaluate the efficacy,
safety and tolerability of laquinimod versus placebo in the treatment of RRMS,
enrolled 1,106 patients and data from the study are expected in Q1 2011.  BRAVO,
 a multinational, multi-center, randomized, parallel-group study designed to
evaluate laquinimod compared to placebo, as well as to provide risk-benefit data
for laquinimod compared to a currently available injectable treatment, Avonex®,
has enrolled 1,332 patients and will be complete in Q3 2011.

In addition to the ongoing RRMS clinical studies, laquinimod is currently in
Phase II development for Crohn's disease and Lupus, and is being studied in
other autoimmune diseases.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top
15 pharmaceutical companies in the world and is the leading generic
pharmaceutical company. The company develops, manufactures and markets generic
and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80
percent of Teva's sales are in North America and Western Europe.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visitwww.activebiotech.comfor more information.

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform Act of 1995:
This  release  contains  forward-looking  statements,  which express the current
beliefs   and   expectations   of  management.  Such  statements  are  based  on
management's  current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results, performance
or  achievements  to  differ  significantly  from  the  results,  performance or
achievements  expressed or implied by such forward-looking statements. Important
factors  that  could  cause  or  contribute  to  such  differences include risks
relating  to: our ability  to successfully develop  and commercialize additional
pharmaceutical  products, the introduction of competing generic equivalents, the
extent  to which we  may obtain U.S.  market exclusivity for  certain of our new
generic  products  and  regulatory  changes  that  may prevent us from utilizing
exclusivity  periods, potential liability for sales of generic products prior to
a  final resolution of outstanding patent litigation, including that relating to
the  generic versions of Neurontin®, Lotrel®,  Protonix® and Yaz®, the extent to
which  any manufacturing or  quality control problems  damage our reputation for
high  quality production, the effects of  competition on sales of our innovative
products, especially Copaxone® (including potential generic and oral competition
for  Copaxone®), the impact of continuing  consolidation of our distributors and
customers,  our  ability  to  identify,  consummate  and  successfully integrate
acquisitions  (including the  acquisition of  ratiopharm), interruptions  in our
supply  chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, intense competition in our specialty
pharmaceutical  businesses, any failures to comply with the complex Medicare and
Medicaid   reporting   and   payment   obligations,  our  exposure  to  currency
fluctuations and restrictions as well as credit risks, the effects of reforms in
healthcare  regulation, adverse effects of  political or economical instability,
major  hostilities or acts of terrorism on our significant worldwide operations,
increased government scrutiny in both the U.S. and Europe of our agreements with
brand  companies,  dependence  on  the  effectiveness  of  our patents and other
protections  for innovative  products, our  ability to  achieve expected results
through  our innovative R&D efforts, the  difficulty of predicting U.S. Food and
Drug  Administration, European  Medicines Agency  and other regulatory authority
approvals,  uncertainties surrounding the legislative and regulatory pathway for
the  registration  and  approval  of  biotechnology-based  products, potentially
significant  impairments of intangible assets  and goodwill, potential increases
in  tax liabilities resulting from  challenges to our intercompany arrangements,
our  potential exposure to product liability claims to the extent not covered by
insurance,  the  termination  or  expiration  of  governmental  programs  or tax
benefits, current economic conditions, any failure to retain key personnel or to
attract  additional  executive  and  managerial  talent, environmental risks and
other  factors that are discussed  in this report and  in our other filings with
the U.S. Securities and Exchange Commission ("SEC").

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This   press   release   contains   certain   forward-looking  statements.  Such
forward-looking  statements involve  known and  unknown risks, uncertainties and
other  important factors  that could  cause the  actual results,  performance or
achievements  of the company, or industry results, to differ materially from any
future  results,  performance  or  achievement  implied  by  the forward-looking
statements.  The company does not undertake any obligation to update or publicly
release   any   revisions  to  forward-looking  statements  to  reflect  events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with  the Swedish Securities  Market Act. The information
was submitted for publication at 3 pm CEST on September 20, 2010.

                                     # # #

Teva Contacts:
|Investor Relations:                |Media:                             |
|Elana Holzman                      |Yossi Koren                        |
|Teva Pharmaceutical Industries Ltd.|Teva Pharmaceutical Industries Ltd.|
|972 (3) 926-7554                   |972 (3) 926-7590                   |
|Kevin Mannix                       |Denise Bradley                     |
|Teva North America                 |Teva North America                 |
|(215) 591-8912                     |(215) 591-8974                     |

Active Biotech Contacts:
|Tomas Leanderson|+46-46-19-20-95|
|Göran Forsberg  |+46-46-19-11-54|



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE